Purchase this article with an account.
A. Saucedo-Castillo, A. Levine-Berebichez, S. Rojas-Juarez; Intravitreal Bevacizumab (Avastin) in Proliferative Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1429.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the efficacy of intravitreal bevacizumab in patients with Proliferative Diabetic Retinopathy.
This is a prospective, experimental, longitudinal and descriptive study. Patients with proliferative diabetic retinopathy with papilar or/and extrapapilar neovascularization without media opacities were included. All patients received 1.8mg (0.07ml) of intravitreal bevacizumab at 3 to 3.5mm from limbus. The patients underwent clinic evaluation with fluorescein angiography control with a minimal follow up of 3 months. In cases where neovascularization persists, conventional photocoagulation was indicated.
40 eyes were included. Mean age was 58 years old. 32.5% had rubeosis, 52.5% papilar neovascularization and 65% extrapapilar neovascularization. We found remission of retinal and papillary neovascularization in 75% of cases during the first month. In 25% of cases the neovascularization persisted at one month, 50% had recurrence at two months and 60% at 3 months of follow up. The papilar neovascularization had shown better response than retinal neovascularization. Vascular changes after intravitreal bevaciazumab injection were observed in 15% of cases. Changes in intraocular pressure were not seen after intravitreal injection.
Bevacizumab induce early remission of neovascularization in patients with proliferative diabetic retinopathy. It could be a therapeutic alternative in these patients as adjunctive treatment of panretinal photocoagulation, reducing the extensive retinal ablation needed to control the proliferative diabetic retinopathy.
Fundacion Hospital Nuestra Senora de la Luz IAP
This PDF is available to Subscribers Only